Vivoryon Therapeutics N.V. (VVY.AS)
| Previous Close | 2.3600 |
| Open | 2.3250 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 2.3250 - 2.4100 |
| 52 Week Range | 0.4100 - 9.9300 |
| Volume | |
| Avg. Volume | 228,190 |
| Market Cap | 62.3M |
| Beta (5Y Monthly) | 1.88 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2000 |
| Earnings Date | Sep 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.10 |
GlobeNewswireVivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024
Halle (Saale) / Munich, Germany, October 11, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that the Company’s abstract “Varoglutamstat Increases Glomerular Filtration in Elderly Patients without Signs of Proteinuria and Potentially Offers a New Approach to Treat Diabetic Kid
- GlobeNewswire
Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Event
Halle (Saale) / Munich, Germany, October 1, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced key takeaways from its virtual Kidney Disease Key Opinion Leader (KOL) Event held September 30, 2024. The event focused on the standard of care and existing medical need, market develop
